Literature DB >> 11159909

A murine tumor progression model for pancreatic cancer recapitulating the genetic alterations of the human disease.

M Wagner1, F R Greten, C K Weber, S Koschnick, T Mattfeldt, W Deppert, H Kern, G Adler, R M Schmid.   

Abstract

This study describes a tumor progression model for ductal pancreatic cancer in mice overexpressing TGF-alpha. Activation of Ras and Erk causes induction of cyclin D1-Cdk4 without increase of cyclin E or PCNA in ductal lesions. Thus, TGF-alpha is able to promote progression throughout G1, but not S phase. Crossbreeding with p53 null mice accelerates tumor development in TGF-alpha transgenic mice dramatically. In tumors developing in these mice, biallelic deletion of Ink4a/Arf or LOH of the Smad4 locus is found suggesting that loci in addition to p53 are involved in antitumor activities. We conclude that these genetic events are critical for pancreatic tumor formation in mice. This model recapitulates pathomorphological features and genetic alterations of the human disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11159909      PMCID: PMC312620          DOI: 10.1101/gad.184701

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  33 in total

Review 1.  CDK inhibitors: positive and negative regulators of G1-phase progression.

Authors:  C J Sherr; J M Roberts
Journal:  Genes Dev       Date:  1999-06-15       Impact factor: 11.361

2.  A mechanism of repression of TGFbeta/ Smad signaling by oncogenic Ras.

Authors:  M Kretzschmar; J Doody; I Timokhina; J Massagué
Journal:  Genes Dev       Date:  1999-04-01       Impact factor: 11.361

3.  A novel method for real time quantitative RT-PCR.

Authors:  U E Gibson; C A Heid; P M Williams
Journal:  Genome Res       Date:  1996-10       Impact factor: 9.043

4.  p19ARF links the tumour suppressor p53 to Ras.

Authors:  I Palmero; C Pantoja; M Serrano
Journal:  Nature       Date:  1998-09-10       Impact factor: 49.962

5.  Cell cycle-dependent activation of Ras.

Authors:  S J Taylor; D Shalloway
Journal:  Curr Biol       Date:  1996-12-01       Impact factor: 10.834

6.  p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma.

Authors:  C A Moskaluk; R H Hruban; S E Kern
Journal:  Cancer Res       Date:  1997-06-01       Impact factor: 12.701

7.  Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF.

Authors:  T Kamijo; F Zindy; M F Roussel; D E Quelle; J R Downing; R A Ashmun; G Grosveld; C J Sherr
Journal:  Cell       Date:  1997-11-28       Impact factor: 41.582

8.  Induction of cell proliferation in quiescent NIH 3T3 cells by oncogenic c-Raf-1.

Authors:  E Kerkhoff; U R Rapp
Journal:  Mol Cell Biol       Date:  1997-05       Impact factor: 4.272

9.  The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53.

Authors:  J Pomerantz; N Schreiber-Agus; N J Liégeois; A Silverman; L Alland; L Chin; J Potes; K Chen; I Orlow; H W Lee; C Cordon-Cardo; R A DePinho
Journal:  Cell       Date:  1998-03-20       Impact factor: 41.582

10.  Malignant transformation of duct-like cells originating from acini in transforming growth factor transgenic mice.

Authors:  M Wagner; H Lührs; G Klöppel; G Adler; R M Schmid
Journal:  Gastroenterology       Date:  1998-11       Impact factor: 22.682

View more
  62 in total

1.  Acinar-to-ductal metaplasia in pancreatic cancer development.

Authors:  Roland M Schmid
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

2.  Aberrant signaling pathways in pancreatic cancer: a two compartment view.

Authors:  Angela L McCleary-Wheeler; Robert McWilliams; Martin E Fernandez-Zapico
Journal:  Mol Carcinog       Date:  2012-01       Impact factor: 4.784

Review 3.  Molecular mechanism of pancreatic cancer--understanding proliferation, invasion, and metastasis.

Authors:  André L Mihaljevic; Christoph W Michalski; Helmut Friess; Jörg Kleeff
Journal:  Langenbecks Arch Surg       Date:  2010-03-18       Impact factor: 3.445

Review 4.  Molecular biology of pancreatic ductal adenocarcinoma progression: aberrant activation of developmental pathways.

Authors:  Andrew D Rhim; Ben Z Stanger
Journal:  Prog Mol Biol Transl Sci       Date:  2010       Impact factor: 3.622

5.  Hedgehog/Ras interactions regulate early stages of pancreatic cancer.

Authors:  Marina Pasca di Magliano; Shigeki Sekine; Alexandre Ermilov; Jenny Ferris; Andrzej A Dlugosz; Matthias Hebrok
Journal:  Genes Dev       Date:  2006-11-15       Impact factor: 11.361

6.  Dissecting the contribution of p16(INK4A) and the Rb family to the Ras transformed phenotype.

Authors:  Philip J Mitchell; Elena Perez-Nadales; Denise S Malcolm; Alison C Lloyd
Journal:  Mol Cell Biol       Date:  2003-04       Impact factor: 4.272

7.  Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma.

Authors:  Andrew J Aguirre; Nabeel Bardeesy; Manisha Sinha; Lyle Lopez; David A Tuveson; James Horner; Mark S Redston; Ronald A DePinho
Journal:  Genes Dev       Date:  2003-12-17       Impact factor: 11.361

8.  The c-myc and PyMT oncogenes induce different tumor types in a somatic mouse model for pancreatic cancer.

Authors:  Brian C Lewis; David S Klimstra; Harold E Varmus
Journal:  Genes Dev       Date:  2003-12-17       Impact factor: 11.361

9.  Galectin-1 drives pancreatic carcinogenesis through stroma remodeling and Hedgehog signaling activation.

Authors:  Neus Martínez-Bosch; Maite G Fernández-Barrena; Mireia Moreno; Elena Ortiz-Zapater; Jessica Munné-Collado; Mar Iglesias; Sabine André; Hans-Joachim Gabius; Rosa F Hwang; Françoise Poirier; Carolina Navas; Carmen Guerra; Martin E Fernández-Zapico; Pilar Navarro
Journal:  Cancer Res       Date:  2014-05-08       Impact factor: 12.701

10.  Effects of Muclin (Dmbt1) deficiency on the gastrointestinal system.

Authors:  Robert C De Lisle; Weihong Xu; Bruce A Roe; Donna Ziemer
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-01-17       Impact factor: 4.052

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.